Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Weekly Update for the Week Ending December 14, 2019

12/16/2019

 
Regulatory Update
 
The FDA approved golodirsen (Vyondys 53, Sarepta Therapeutics) on 12/12/2019 for the treatment of Duchenne muscular dystrophy amenable to exon 53 skipping. We took a look at this surprise reversal of the August 2019 rejection of the drug in a post last week.
 
The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 12-0 to recommend approval of Horizon Therapeutics’ teprotumumab in December 2019 for the treatment of Thyroid Eye Disease.
 
The FDA lifted the clinical trial hold for Abeona Therapeutics’ EB-101 targeting recessive dystrophic epidermolysis bullosa
 
The FDA designated Dermira/Roche’s lebrikizumab a Fast Track treatment for moderate-to-severe atopic dermatitis.
 
The FDA Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against recommending approval of Correvio’s vernakalant due to safety concerns over hypotension, arrhythmias, and conduction disturbance.
 
Biocryst submitted an NDA for BCX7353 in December 2019 with a hereditary angioedema indication.
 
Seattle Genetics plans to file an NDA and MAA for tucatinib in 1Q20.
 
Announced Research Updates
  1. Bluebird Bio announced that in the 5-year, 23 patient, Phase I/II, open-label Northstar Trial, treatment with elivaldogene tavalentivec resulted in transfusion independence (Hemoglobin of at least 9 g/dL and no transfusions for more than 12 months) in 8 out of 10 beta-thalassemia patients without the beta 0/beta 0 genotype and 3 out of 8 who did. 
  2. Iterum Therapeutics announced that in the 668 patient, Phase III SURE 3 trial, IV sulopenem followed by oral sulopenem/probenecid did not meet non-inferiority compared to to IV ertapenem followed by oral ciprofloxacin/metronidazole or amoxicillin-clavulanate in the treatment of complicated intra-abdominal infections.
  3. Leo Pharma announced the results from three Phase III trials (ECZTRA 1, 2 and 3) involving 1,976 patients with moderate-to-severe atopic dermatitis who were candidates for systemic therapy. In the trials more patients treated with tralokinumab with or without topical corticosteroids achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin at week 16 and at least a 75% or > improvement in their Eczema Area and Severity Index (EASI) score at week 16 compared to placebo. The FDA has given tralokinumab and orphan drug priority designation.
  4. MacroGenics announced interim data from the 563 patient, Phase III, SOPHIA trial, where margetuximab plus one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine) resulted in overall survival of 21.6 months compared to 19.8 months with trastuzumab and one of four chemotherapy agents in previously treated HER-2 positive metastatic breast cancer patients who were receiving standard chemotherapy. There was no difference in progression-free survival between the two drugs.
  5. Mustang Bio announced updated interim data from 11 XSCID infants that completed 23.6-months in a Phase I/II, open-label trial, suggested that treatment with MB-107 lead to normal for age levels of NK cells in 3-4 months in 9 patients.
  6. Cara announced that in a 12-week, Phase II trial, treatment with oral difelikefalin 1 mg improved the daily 24-hour Worst Itching Intensity Numeric Rating Scale (WI-NRS) score compared to placebo (-4.4 vs -3.3) in patients with CKD-associated pruritus.
Published Research Updates
  1. In the 24-hour, 768 patient, Phase III, open-label ATHENA trial, treatment with Travena’s oliceridine reduced the NRS pain score by 2.2 points at 30 mins from a baseline score of 6.3 in surgical (94%) and non-surgical patients with moderate to severe acute pain.
  2. In the 184 patient, Phase II, open-label, DESTINY-Breast01 trial, treatment with AstraZeneca/ Daiichi Sankyo’strastuzumab deruxtecan resulted in an objective response rate of 60.9% of patients with HER2 positive metastatic breast cancer previously treated with trastuzumab emtansine.
  3. In a 21-week, 38-patient, Phase II trial, 46% of patients treated with Argenx’ efgartigimod added to standard of care therapy improved their platelet count to 50x109/L during two or more visits compared to 25% in the placebo cohort in patients with primary immune thrombocytopenia (ITP).
  4. A 52-week, 172 patient, open-label extension of a 14-week efficacy trial examined the safety for Daiichi Sankyo’s mirogabalin and found the most common adverse effect to be nasopharyngitis, diabetic retinopathy, peripheral edema, somnolence, diarrhea, increased weight, and dizziness in Asian patients with diabetic peripheral neuropathic pain.
  5. ​In the 1-year, 480 patient, Phase II, HER2CLIMB trial, treatment Seattle Genetics tucatinib in combination with trastuzumab and capecitabine resulted in progression-free survival in 33.1% of patients compared to 12.3% with trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab and trastuzumab emtansine.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.